Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Program Title

Cost-effective Management of NSAID-related Cardiovascular and Gastrointestinal Risk: Clinical Presentation, Risks, and Therapeutic Options
Release Date: May-26-06
Credit Expiration Date: May-26-07

Faculty

James M. Scheiman, MD
Professor, Internal Medicine
Division of Gastroenterology
University of Michigan Medical Center
Ann Arbor, MI

A. Mark Fendrick, MD
Professor, Internal Medicine and Health
Management & Policy
Division of General Medicine
University of Michigan Medical Center
Co-Editor in Chief, American Journal of Managed Care
Ann Arbor, MI

Credit Hours

1

Medium

Online Presentation

Program Description

This program is the first part of a two-part series based on live audioconfence presentations.

In this program, the biology of NSAIDs and other antiinflammatory agents such as aspirin and antiplatelet agents is reviewed, along with their attendant risks, specifically those risks associated with the cardiovascular and gastrointestinal systems. Amelioration of some of these risks with gastroprotective cotherapy is discussed, including use of PPIs, prostaglandins, and NSAID/prostaglandin combination products. Assessing and managing patients with multiple risk factors from the standpoint of efficacy, improved patient outcomes, and cost-effectiveness can be a challenge; specific strategies will be discussed.

Program Developer/Facilitator


.

Target Audience

Managed Care Medical Directors, Pharmacy Directors, Physicians, and Pharmacists.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review clinical trials regarding the cardiovascular and gastrointestinal implications of chronic NSAID use
  2. Provide clinicians with a rational guide for managing competing CV and GI risks related to anti-inflammatory drug therapy
  3. Identify and discuss the clinical and economic impact of gastroprotective strategies to reduce GI complications

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.

James M. Scheiman, MD discloses that he has received grant/research support from AstraZeneca; is a consultant for AstraZeneca, Merck, Nitromed, McNeil, Novartis, TAP, Pfizer, The GI Company, and Pozen; and is on speakers bureaus for AstraZeneca, TAP, Boheringer Ingelheim and Santarus.

A. Mark Fendrick, MD discloses that he is a consultant, a member of advisory committes, and on speakers bureaus for Merck, AstraZeneca, Merck-Medco, Proctor & Gamble, GlaxoSmithKline, Pfizer, Eli Lilly and Co., TAP Pharmaceuticals, Aventis Pharmaceuticals and Amgen.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in each activity.

AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This activity has been assigned the Universal Program Number 077-999-06-035-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.

Commercial Support Statements

This activity is supported by an educational grant from AstraZeneca.

Instructions

  1. Please turn off all pop-up blockers and click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. The next screen will permit you to check for or download the Flash player required to run this program. Clicking on the "slides" button on this screen will begin the program presentation. Clicking on the "Q and A" button will bring you to the pre-recorded question and answer session. The program, Q and A, post-test and evaluation will take approximately 60 minutes to complete.
  3. Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.

Certificate Fee

$0.00

Disclaimer

None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this publication and audioconference are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS